clinical trial · NCT01773928
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
Alachua Government Services, Inc.·phase3·completed·n = 1,928
InfluenzaVero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)VCIV manufactured with the current manufacturing process (VCIV current)Fluzone®, licensed trivalent influenza vaccine (TIV)
brief summary
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1. induces immune responses comparable to that produced by the current manufacturing process 2. has an acceptable safety profile compared to a licensed trivalent seasonal influenza vaccine 3. demonstrates consistency of immune response among three different lots.
started
Jan 1, 2013
primary completion
Apr 1, 2013
completion
Apr 1, 2013
last updated
Sep 11, 2025
official title
Randomized, Age-stratified, Double Blind, Controlled Phase 3 Study Comparing a Vero Cell-derived Trivalent Seasonal Influenza Vaccine Made by the Modified Manufacturing Process With Vaccine Made by the Current Manufacturing Process and a Licensed Trivalent Influenza Vaccine in Healthy Adults Aged 18 Years and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol